Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature

While cancer is often related to hyperfibrinogenemia, it is rarely related to hypofibrinogenemia. Specifically, gastric cancer concomitant with unprovoked hypofibrinogenemia and the corresponding treatment approach have been rarely reported. We presented a case of gastric cancer in a 78-year-old Chi...

Full description

Bibliographic Details
Main Authors: Shuzhen Ma, Qi Dang, Yali Yang, Yongliang Liu, Yuping Sun, Meili Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
sintilimab
immunotherapy
hypofibrinogenemia
gastric cancer
case report
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.526096/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.526096/full

Similar Items